Bahadır Batar

Bahadır Batar

Auto-generated profile, based on publicly available information

Bahadır Batar


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Gene
Verified
Journal Article
Closed access
BBBahadir Batar
Bahadir Batar
IBIsil Bavunoglu
Isil Bavunoglu
YHYalcin Hacioglu
Yalcin Hacioglu
MCMahir Cengiz
Mahir Cengiz
TMTuba Mutlu
Tuba Mutlu
MGMehmet Guven
Mehmet Guven

12 January 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
AYAlpay Yeşilaltay
Alpay Yeşilaltay
DMDilek Muz
Dilek Muz
BEBerna ERDAL
Berna ERDAL
TBTürker Bilgen
Türker Bilgen
BBBahadır Batar
Bahadır Batar
BABurcu Altındağ Avcı
Burcu Altındağ Avcı
This study aimed to explore the effectiveness and safety of Myxoma virus (MYXV) in MM cell lines and primary myeloma cells obtained from patients with multiple myeloma. Myeloma cells were isolated from MM patients and cultured. MYXV, lenalidomide, and bortezomib were used in MM cells. The cytotoxicity assay was investigated using WST-1. Apoptosis was assessed through flow cytometry with Annexin V/PI staining and caspase-9 concentrations using ELISA. To explore MYXV entry into MM cells, monoclonal antibodies were used. Moreover, to explore the mechanisms of MYXV entry into MM cells, we examined the level of GFP-labeled MYXV within the cells after blocking with monoclonal antibodies targeting BCMA, CD20, CD28, CD33, CD38, CD56, CD86, CD117, CD138, CD200, and CD307 in MM cells. The study demonstrated the effects of treating Myxoma virus with lenalidomide and bortezomib. The treatment resulted in reduced cell viability and increased caspase-9 expression. Only low-dose CD86 blockade showed a significant difference in MYXV entry into MM cells. The virus caused an increase in the rate of apoptosis in the cells, regardless of whether it was administered alone or in combination with drugs. The groups with the presence of the virus showed higher rates of early apoptosis. The Virus, Virus + Bortezomib, and Virus + Lenalidomide groups had significantly higher rates of early apoptosis (p < 0.001). However, the measurements of late apoptosis and necrosis showed variability. The addition of MYXV resulted in a statistically significant increase in early apoptosis in both newly diagnosed and refractory MM patients. Our results highlight that patient-based therapy should also be considered for the effective management of MM.

20 March 2025 in Acta Chimica Slovenica
Verified
Journal Article
Open access
PDF file
MAMerve Argon
Merve Argon
TSTemine Sabudak
Temine Sabudak
BYBuse Nur Yıldırım
Buse Nur Yıldırım
BBBahadır Batar
Bahadır Batar
HOHakime Hülya Orak
Hakime Hülya Orak
HCHilmican Calıskan
Hilmican Calıskan
The aim of this study was to investigate the anticancer and antioxidant activities of Genista januensis subsp. lydia (Fabaceae) extracts and to isolate the phytochemical compounds responsible for these activities. The G. januensis plant was extracted by maceration with solvents of increasing polarity. The total phenolic/flavonoid content, antioxidant activities and anticancer activity were investigated by performing cytotoxicity, apoptosis and cell cycle analyses in crude extracts. We found that the EtOAc extract had the highest antioxidant and anticancer activities and this extract was selected for isolation studies. All purified flavonoid compounds from the EtOAc extract were elucidated using 1D and 2D NMR and mass spectroscopic methods and compared with the literature. A new biflavonoid 4 was isolated together with three known isoflavonoids (genistein (1), genistin (2) and 4’-hydroxyisoflavone (3)) from Genista januensis subsp. lydia (Fabaceae). MTT analysis of compounds 2, 3, and 4 was used to evaluate the anticancer activity. Compound 4 was invesigated for its antioxidant activities. These findings suggest that G. januensis subsp. lydia represents new potential natural sources of effective antiproliferative and antioxidant agents.

18 July 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
AHAYŞEN HAKSAYAR
AYŞEN HAKSAYAR
MDMustafa Metin Donma
Mustafa Metin Donma
BBBahadır Batar
Bahadır Batar
BTBuse Tepe
Buse Tepe
BTBirol Topçu
Birol Topçu
ODOrkide Donma
Orkide Donma
Background/Objectives: Obesity is associated with cardiovascular disease worldwide. An increased lipoprotein A (LpA) level is an independent risk factor for cardiovascular disease in children. Genetic polymorphisms of the LPA gene may play an important role in susceptibility to obesity. The aim of this study was to investigate the association of LPA rs10455872 polymorphism with the risk and clinical phenotypes of childhood obesity. Methods: This study included 103 children with obesity and 77 healthy controls. Genotyping of the LPA rs10455872 polymorphism was performed using real-time PCR. Results: The genotype distributions of the LPA rs10455872 polymorphism did not differ significantly between children with obesity and healthy children (p = 0.563). A marked difference in insulin levels was observed between children with obesity carrying the AG (16.90 IU/mL) and AA (25.57 IU/mL) genotypes. A marked difference was also observed in CRP levels between children with obesity with the AG (2.31 mg/L) and AA (4.25 mg/L) genotypes. After correcting for multiple comparisons using the false discovery rate (FDR), significant differences were found between AG and AA genotypes in vitamin B12 (adjusted p = 0.024). Serum iron showed a borderline association (adjusted p = 0.072). A statistically significant correlation was found between the metabolic syndrome index and body fat ratio among children with obesity with the AA genotype (p = 0.028). Conclusions: Although limited by the small number of children with obesity with the AG genotype, some differences were noted between the AG and AA genotypes. These exploratory findings require further investigation in adequately powered studies. In children with obesity with the AA genotype, the metabolic syndrome index increases as the body fat ratio increases.